FibroGen, Inc. — Form 10-Q Summary
Entity note: The supplied filing identifies the registrant as FibroGen, Inc., not Kyntra Bio, Inc. This summary reflects the filing provided. Reporting period ended September 30, 2018; financial statements are unaudited.
Business context and reporting period
FibroGen is a clinical-stage biopharmaceutical company. Its lead candidate, roxadustat, was in Phase 3 development for anemia associated with chronic kidney disease (CKD) and myelodysplastic syndromes (MDS). Pamrevlumab was in Phase 2 development for idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). Revenue came substantially from development collaborations with Astellas and AstraZeneca; FibroGen had no revenue from approved product sales.
Financial results and position
| Metric | Three months ended Sep. 30, 2018 | Nine months ended Sep. 30, 2018 | Comparable 2017 period |
|---|---|---|---|
| Revenue | $29.0 million | $104.9 million | $40.6 million; $100.3 million |
| Operating expenses | $71.8 million | $211.5 million | $63.3 million; $182.0 million |
| Operating loss | $42.8 million | $106.6 million | $22.7 million; $81.7 million |
| Net loss | $42.6 million | $107.4 million | $24.5 million; $87.0 million |
| Net loss per share, basic and diluted | $0.50 | $1.28 | $0.32; $1.24 |
For the quarter, revenue fell 28% year over year, while operating expenses rose 13%. For the nine months, revenue increased 5% and operating expenses rose 16%. R&D expense was $165.6 million for nine months, led by roxadustat ($104.7 million) and pamrevlumab ($42.8 million). Stock-based compensation was $38.4 million for the nine months, versus $27.6 million in 2017. Reported losses exceeded revenue in both periods; calculated operating-loss margin was approximately 147% for the quarter and 102% for the nine months.
Cash flow and liquidity: Cash and cash equivalents were $566.7 million at September 30, 2018, down from $673.7 million at year-end 2017. Short- and long-term investments totaled $126.6 million; accounts receivable was $23.2 million. Cash, investments, and receivables totaled $716.5 million. Current assets were $678.8 million and current liabilities $100.4 million. Operating cash use was $58.7 million for the nine months, versus $65.3 million in 2017. Investing activities used $59.3 million, primarily reflecting purchases of securities; financing provided $11.1 million, mainly from stock-option exercises and employee stock purchases.
Debt and obligations: The filing reports $97.3 million of long-term lease financing obligations, with a fair value of $98.2 million. It also reports $16.9 million in product development obligations. The filing does not identify conventional borrowings as a material balance-sheet item.
FibroGen stated that cash, investments, and receivables should cover anticipated cash requirements for at least 12 months from the filing date, while cautioning that assumptions could change and additional financing might be needed. No formal revenue or earnings guidance was provided.
Material changes, outlook, and notable items
- Quarterly revenue was lower mainly because the prior-year quarter included revenue recognition related to a $15 million AstraZeneca China NDA milestone. Nine-month revenue was higher mainly because a $15 million Astellas Japan NDA-submission milestone became probable in Q2 2018; $14.9 million was recognized across performance obligations.
- Operating-cost growth reflected higher stock compensation, employee costs, pamrevlumab drug-substance manufacturing, and facility costs. Lower trial costs partly offset these increases as roxadustat Phase 3 and pamrevlumab Phase 2 trials approached completion.
- Management expected topline results from U.S. and European roxadustat CKD Phase 3 studies in Q4 2018, subject to progress in MACE adjudication, and pooled safety data before a U.S. NDA submission in the first half of 2019. China’s review of the roxadustat NDA continued; management anticipated a decision for dialysis-dependent CKD by year-end 2018 and a decision on adding non-dialysis-dependent CKD to the label in the first half of 2019, subject to site inspections.
- FibroGen planned to begin Phase 3 pamrevlumab trials for pancreatic cancer and IPF in Q1 2019. Management expected R&D expense to rise as these trials began.
- A $20.9 million roxadustat API transfer to Astellas for manufacturing validation was recorded as deferred revenue because Astellas’ right to use the material was limited at quarter-end. FibroGen and Astellas were negotiating a Japan Agreement amendment to permit Astellas to manufacture drug product while FibroGen continued supplying API.
- FibroGen adopted ASC 606 using the full retrospective method, recasting 2017 comparisons. The change affected revenue timing and classification, but not previously reported cash flows. Milestone and co-development revenue estimates involve significant judgment.
- Key risks include clinical-trial outcomes and safety, including cardiovascular endpoints; regulatory approval and timing; dependence on Astellas and AstraZeneca for roxadustat development and commercialization; manufacturing capacity and licensing, particularly in China; competition and reimbursement; and possible need for additional financing. The filing reported no material legal proceedings and no material change in contractual obligations from the 2017 Form 10-K.
Most important facts for investors to verify
- Whether roxadustat trial results, MACE analyses, and regulatory decisions met the stated timelines and requirements.
- Whether the Astellas Japan amendment was completed and how deferred revenue from the API transfer was recognized.
- Whether collaboration funding, reimbursements, and milestones continue as planned, and how much future development spending FibroGen must fund itself.
- Whether the stated 12-month liquidity outlook remains supportable as clinical and planned Phase 3 costs increase.
- How ASC 606 milestone estimates and collaboration revenue timing affect period-to-period comparisons.